An NCI-designated Comprehensive Cancer Center

Jana Portnow, M.D.

Medical Oncologist
Clinical Expertise
Research Focus
  • Gliomas
  • brain metastases
Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research; Associate Director, Brain Tumor Program

Clinical Teams

Jana Portnow, M.D., is an associate clinical professor in the Department of Medical Oncology & Therapeutics Research.
Dr. Portnow earned her undergraduate degree at Brown University and her medical degree from University of Rochester School of Medicine. She completed her internal medicine residency at Temple University Hospital, where she was chosen to do an additional year of teaching and administration as a chief resident. She then completed fellowships in oncology and neuro-oncology at Johns Hopkins Medical Center before joining the faculty at City of Hope in 2002.
She is Associate Director of City of Hope's Brain Tumor Program and clinical leader of the neural stem cell brain tumor research program. Nationally, she serves as vice-chairperson of the National Comprehensive Cancer Network Guidelines Panel for CNS Cancers, and she reviews grant applications as a member of the National Institute of Health (NIH) Clinical Oncology Study Section.
Her research interests include early drug development, with an emphasis on understanding if new chemotherapies can cross the blood-brain barrier and achieve sufficient concentrations in the brain. She has expertise in performing early phase clinical trials of cellular therapies and is currently the principal investigator of a first-in-human study of genetically modified neural stem cells in patients with recurrent high grade gliomas, as well as a first-in-human study of CAR T cells for the treatment of brain metastases.
Dr. Portnow has numerous peer-reviewed publications and has received research funding from the NIH/National Cancer Institute, U.S. Food and Drug Administration, California Institute of Regenerative Medicine and Phase One Foundation.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

Early changes in tumor perfusion from dynamic contrast enhanced T1-weighted MRI following neural stem cell-mediated therapy for recurrent high grade gliomas correlates with overall survival. 
Sahoo, P., Frankel, P.H., Ressler, J., Gutova, M., Annala, A.J., Badie, B., Portnow, J.,
Aboody, K.S., D’Apuzzo, M., Rockene, R.C.. 
Stem Cells Int. 2018 Mar 14;2018:5312426.  
PMID: 29731779 PMCID: PMC5872616 

Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2+ breast cancer metastasis to the brain.
Priceman, S.J., Tilakawardane, D., Jeang, B., Murad, J.P., Park, A.K., Chang, W., Ostberg, J., Neman, J., Jandial, R., Portnow, J., Forman, S.J., & Brown, C.E. 
Clin Cancer Res. 2018 Jan 1;24(1):95-105.
PMID: 29061641
Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients.  
Portnow, J., Synold, T.W., Badie, B., Tirughana, R., Lacy, S.F., D’Apuzzo, M., Metz, M.,
Najbauer, J., Bedell, V., Vo, T., Gutova, M., Frankel, P., Chen, M., & Aboody, K.
Clin Cancer Res. 2017 Jun 15;23(12):2951-2960.
PMID: 27979915
Regression of glioblastoma after chimeric antigen receptor T-cell therapy. 
Brown, C.E., Alizadeh, D., Starr, R., Weng, L., Wagner, JR., Naranjo, A., Ostbert, J.R., Blanchard, S., Kilpatrick, J., Simpson, J., Kurien, A., Priceman, S.J., Wang, X., Harshbarger, T.L., D’Apuzzo, M., Ressler, J.A., Jensen, M.C., Barish, M.E., Chen, M., Portnow, J., Forman, S.J., & Badie, B. 
N Engl J Med. 2016 Dec 29;375(26):2561-9.
PMID: 28029927 PMCID: PMC5390684
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.
Wheeler, L.A., Manzanera, A.G., Bell, S.D., Cavliere, R., McGregor, J.M., Grecula, J.C., Newton, H.B., Lo, S.S., Badie, B., Portnow, J., Teh, B.S., Trask, T.W., Baskin, D.S., New, P.Z., Aguilar, L.K., Aguilar-Cordova, E., & Chiocca, E.A.
Neuro-Oncology, 2016 Aug;18(8):1137-45. 
PMCID: PMC4933478
Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. 
Brown, C.E., Badie, B., Barish, M.E., Weng, L., Ostberg, J.R., Chang, W.C., Naranjo, A., Starr, R., Wagner, J., Wright, C., Zhai, Y., Bading, J.R., Ressler, J.A., Portnow, J., D'Apuzzo, M., Forman, S.J., & Jensen, M.C. 
Clin Cancer Res. 2015 Sep 15;21(18):4062-72. 
PMID: 26059190 PMCID: PMC4632968
A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent.
Portnow, J., Badie, B., Liu, X., Frankel, P., Mi, S., Chen, M., & Synold, T.W.
J Neurooncol. 2014 May;118(1):169-77. 
PMCID: PMC4581878 
Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Metz, M.Z., Gutova, M., Lacey, S.F., Abramyants, Y., Vo, T., Gilchrist, M., Ghodoa, L.Y.,
Barish, M.D., Brown, C.E., Najbauer, J., Potter, P.H., Portnow, J., Synold, T.W., Aboody,
Stem Cells Transl Med. 2013 Dec;2(12):983-92.
PMCID: PMC3841093 
A Neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas.
Portnow, J., Badie, B., Markel, S., Liu, A., D’Apuzzo, M., Frankel, P., Jandial, R., & Synold, T.W. 
Eur J Cancer. 2013 May; 49(7):1634-40.
PMID: 23380277 PMCID: PMC4172445
Neural stem cell-mediated enzyme-prodrug therapy for glioma: preclinical studies.
Aboody, K.S., Najbauer, J., Metz, M.Z., D’Apuzzo, M., Gutova, M., Annala, A.J., Synold,
T.W., Couture, L.A., Blanchard, S., Moats, R.A., Garcia, E., Aramburo, S., Valenzuela, V.V.,
Frank, R.T., Barish, M.E., Kim, S.U., Badie, B., & Portnow, J.
Sci Transl Med. 2013 May 8;5(184):184ra59. 
PMID: 23658244 PMCID: PMC3864887
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Portnow, J., Frankel, P., Koehler, S., Twardowski, P., Shibata, S., Martel, C., Morgan, R., Cristea, M., Chow, W., Lim, D., Chung, V., Reckamp, K., Leong, L., & Synold, T.W.
Cancer Chemother Pharmacol. 2012 Feb;69(2):505-14.
PMCID: PMC3506384
Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development.
Blakeley, J., & Portnow, J.
Expert Opin Drug MetabToxicol. 2010 Dec;6(12):1477-91. 
PMCID: PMC3994531 
The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. 
Portnow, J., Badie, B., Chen, M., Liu, A., Blanchard, S., & Synold, T.W.
Clin Cancer Res. 2009 Nov 15;15(22):7092-8.
PMCID: PMC2908372
Assessment of pain caused by invasive procedures in cancer patients.
Portnow, J., Lim, C., & Grossman, S.A.
J Natl Compr Canc Netw. 2003 Jul;1(3):435-9.
PMID: 19761075
A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas.
Portnow J., Suleman, S., Grossman, S.A., Eller, S., & Carson, K.
Neuro Oncol. Neuro Oncol. 2002 Jan; 4(1):22-5.  
PMCID: PMC1920630.
In The News
An Expert's Voice
Breast Cancer Cell 500X500

Moving toward the next
level in breast cancer CAR T cell therapy


First-of-its-kind CAR T clinical trial enrolls HER2+ breast cancer patients with brain metastases

Pancreatic Cancer Cell

Groundbreaking new CAR T cell trial opens for patients with breast cancer that has spread to the brain